# Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

> **NCT04282044** · PHASE1 · RECRUITING · sponsor: **BioEclipse Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Triple Negative Breast Cancer
- Colorectal Cancer
- Hepatocellular Carcinoma
- Osteosarcoma
- Epithelial Ovarian Cancer
- Gastric Cancer
- Non-small Cell Lung Cancer
- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** CRX100 suspension for infusion
- **COMBINATION_PRODUCT:** Fludarabine
- **COMBINATION_PRODUCT:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04282044
- **Lead sponsor:** BioEclipse Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-08
- **Primary completion:** 2025-08
- **Final completion:** 2026-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04282044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04282044, "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04282044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*